目的:本研究的目的是评估患者的特征,伴随的镇痛药物,以及德国现实世界中的疼痛强度,重点是反复应用高浓度辣椒素贴片(HCCP)治疗神经性疼痛。
方法:数据来自2011年1月至2022年7月期间接受至少两次HCCP治疗的患者的电子病历。根据HCCP治疗的数量进行亚组分析,年龄组,和特定的神经性疼痛状况。
方法:这项研究是在威斯巴登的门诊疼痛中心进行的,德国。
方法:该研究包括97名患者,主要诊断为神经性背痛,术后或创伤后神经性疼痛,和带状疱疹后神经痛.
方法:合并用药的每日剂量(例如,阿片类药物和抗惊厥药)在辣椒素治疗开始时与辣椒素治疗2年内的平均值进行比较。如果在2年期限结束之前停止HCCP治疗,则使用最后一次观察结转方法。
结果:大多数患者接受了合并用药,阿片类药物,抗惊厥药,抗抑郁药是最常见的。在HCCP治疗期间,平均每日吗啡当量剂量显着降低。基线时的疼痛强度通常较高,但在接受至少3例HCCP应用的患者中观察到显著改善.
结论:这项研究为HCCP治疗在降低神经性疼痛患者的疼痛强度和伴随使用阿片类药物方面的有效性提供了证据。需要进一步的研究来探索不同患者人群的长期结果和最佳治疗方案。
OBJECTIVE: The aim of this study was to evaluate patient characteristics, concomitant analgesic medication, and pain intensity in a real-world setting in Germany, focusing on the repeated application of high-concentration
capsaicin patch (HCCP) for neuropathic pain.
METHODS: Data were collected from electronic medical records of patients who received at least two HCCP treatments between January 2011 and July 2022. Subgroup analyses were performed based on the number of HCCP treatments, age groups, and specific neuropathic pain conditions.
METHODS: The study was conducted at an outpatient pain center in Wiesbaden, Germany.
METHODS: The study included 97 patients, primarily diagnosed with neuropathic back pain, postoperative or post-traumatic neuropathic pain, and postherpetic neuralgia.
METHODS: The daily dose of concomitant medications (eg, opioids and anticonvulsants) at the start of
capsaicin therapy was compared with the average within 2 years of
capsaicin therapy. The last observation carried forward method was used if HCCP treatment was discontinued before the end of the 2-year period.
RESULTS: The majority of patients received concomitant medications, with opioids, anticonvulsants, and antidepressants being the most common. The average daily morphine equivalent dose decreased significantly during HCCP treatment. Pain intensity at baseline was generally high, but substantial improvements were observed in patients who received at least three HCCP applications.
CONCLUSIONS: This study provides evidence for the effectiveness of HCCP treatment in reducing pain intensity and concomitant opioid use in patients with neuropathic pain. Further research is needed to explore the long-term outcomes and optimal treatment regimens for different patient populations.